@article{Thanee_Lertnawapan_Sritipsukho_Nanthapisal_Kulalert_Tanticharoenwiwat_Achararit_Tantilipikorn_Poachanukoon_2022, title={Efficacy of Zingiber cassumunar Roxb (Phlai capsule) Compare with Loratadine as Treatment in Allergic Rhinitis Patients (Preliminary Results)}, volume={22}, url={https://asianmedjam.com/index.php/amjam/article/view/1247}, abstractNote={<p><strong>Introduction:</strong> Phlai capsules can inhibit skin reactivity in allergic rhinitis patients. <br /><strong>Objectives:</strong> The aim of this study was to compare the efficacy of Phlai capsules with Loratadine in allergic rhinitis patients.<br /><strong>Methods:</strong> This was a multi-center, prospective, randomized, double-blinded, placebo-controlled study in 50 patients, aged 18-50 years old, who randomly received 4 mg or 8 mg Phlai capsules or Loratadine for 8 weeks. The primary efficacy endpoint was Total Symptoms Score at 4 and 8 weeks. The secondary endpoints were peak nasal inspiratory flow and quality of life.<br /><strong>Results:</strong> Demographic data was similar between groups. The change in 6-Total symptoms score decreased significantly from baseline. Peak nasal inspiratory flow increased with no significant differences between groups. According to the RCQ-36 questionnaire, there wassignificant improvement in quality of life for every domain, including sleep and emotion.<br /><strong>Conclusions:</strong> Phlai capsules reduced rhinitis symptoms and improved quality of life.</p>
<p><strong> </strong></p>}, number={-}, journal={Asian Medical Journal and Alternative Medicine}, author={Thanee, Patrada and Lertnawapan, Ratchaya and Sritipsukho, Paskorn and Nanthapisal, Sira and Kulalert, Prapasri and Tanticharoenwiwat, Pattara and Achararit, Nitchanan and Tantilipikorn, Pongsakorn and Poachanukoon, Orapan}, year={2022}, month={Aug.}, pages={S15-S21} }